AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01822574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haptic Feedback Technique
Description: It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
Study NCT01822574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Quadrant Technique
Description: Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
Study NCT02582866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: * Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration
Study NCT06429319 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hydrous biopolymer with silver ions Argiform
Description: Patients will receive an injection of MD NOLTREX™ into the target knee joint. MD will be administered in accordance with the instructions for use of MD NOLTREX™: 4.0 ml per injection (2.5 + 1.5 ml, or 2.0 + 2.0 ml from two syringes through one needle \[one puncture\]) at intervals of one week. The course within this open study is a maximum of 2 injections. The number of injections is determined by the doctor depending on the stage of gonarthrosis and the clinical response
Study NCT02963441 — intervention group
Intervention type: DEVICE
Intervention: LumineticsCore (formerly IDX-DR)
Description: Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
Study NCT00814918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA with Blu-U Light
Description: 20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
Study NCT00814918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA with Candela V-beam Pulse Dye Laser
Description: 20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
Study NCT03055663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation by watching virtual reality sedative program
Description: Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
Study NCT03055663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation by using intravenous sedative
Description: Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
Study NCT03055663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
Study NCT02071849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 200 Aortic Valve Annuloplasty Device
Description: Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
Study NCT04144114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProHydrolase®
Description: Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
Study NCT03331224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC
Description: OTSC placement
Study NCT03331224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Standard therapy (combining two methods)
Description: endoscopic standard therapy (two methods, e.g. clip and injection)
Study NCT03714347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oxygen monitoring
Description: probes will be placed on eyebrows on forehead
Study NCT03714347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine monitoring
Description: We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
Study NCT03750071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
Study NCT03750071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal anti-PD-L1 Antibody
Study NCT00405652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate sodium (EC-MPS)
Description: experimental
Study NCT02001363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide (Novo Nordisk, Bagsværd, Denmark)
Description: once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
Study NCT02001363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide placebo (Novo Nordisk)
Description: once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
Study NCT04144114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Subjects received 25g of whey protein powder mixed to together in a drink
Study NCT04144114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00499200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA-444
Study NCT02394158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02394158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05278026 — intervention group
Intervention type: OTHER
Intervention: guideline recommended routine treatment
Study NCT02487966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): active (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
Study NCT02487966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy: active
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
Study NCT02487966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
Study NCT02487966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
Study NCT00293150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study NCT00293150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Study NCT00821145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: AAA patients operated using a conventional incision
Study NCT00821145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic AAA resection
Description: laparoscopic AAA resection
Study NCT00821145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic stapler anastomosis
Description: laparoscopic AAA resection, proximal anastomosis performed with a stapler
Study NCT01019252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
Study NCT02487966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy: Sham
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
Study NCT02487966 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mirror Therapy: Sham
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
Study NCT05046626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
Study NCT01951898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10mg/day, once a daily after dinner, for 28dyas
Study NCT01951898 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Montelukast
Description: 10mg/day, once a daily after dinner, for 28dyas
Study NCT00222742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induced moderate hypothermia
Description: Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
Study NCT03400241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product A
Study NCT03400241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product B
Study NCT03400241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product C
Study NCT03400241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide Monohydrate
Description: Spiriva 18 Mcg/capsule inhaled via HandiHaler
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin at the protocol-defined dose and regimen.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil at the protocol-defined dose and regimen.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the protocol-defined dose and regimen.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at the protocol-defined dose and regimen.
Study NCT03314935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at the protocol-defined dose and regimen.
Study NCT00869167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: melatonin agonist
Study NCT00869167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon
Description: melatonin agonist
Study NCT02043990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive NAVA ventilation
Description: Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
Study NCT00366210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement (CI) Therapy
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Study NCT00366210 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching, Relaxation, & Biofeedback
Description: Passive stretching of both arms, EMG biofeedback for more-impaired arm
Study NCT04906031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Description: Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
Study NCT01117194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)
Description: Use an intelligent robot to assist upper limb rehabilitation.
Study NCT01196013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Intravenous, 30 mg/m2, 52 mg/m2
Study NCT03576261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative colloid fluid bolus (Gelofusine)
Description: Preoperative colloid fluid bolus
Study NCT03576261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative transthoracic echocardiography
Description: Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
Study NCT03576261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative transthoracic echocardiography
Description: Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
Study NCT00932074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-413 Ointment
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Study NCT00932074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KP-413 Ointment
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Study NCT00974155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram, venlafaxine, lithium
Description: oral application, highest tolerable dose, once daily
Study NCT00974155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram, venlafaxine
Description: oral application, highest tolerable dose, once daily
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Study NCT04268069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PL9643 Ophthalmic Solution
Description: PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Study NCT04268069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Study NCT03308682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE
Description: The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Study NCT04410159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Gargle
Study NCT04410159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Gargle
Study NCT04410159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tap water
Description: Gargle
Study NCT00891696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Single 16-mg oral dose
Study NCT00891696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00891696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00877006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study NCT00489372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Se-methyl-seleno-L-cysteine
Description: Given orally
Study NCT00489372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00489372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00489372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00489372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00489372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01121003 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight maintenance, low sugar diet
Study NCT01121003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight maintenance, high fructose diet
Study NCT01121003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight maintenance, high fructose diet+ exercise
Study NCT03288324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg twice daily
Study NCT03483766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Functional Rehabilitation system
Description: The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
Study NCT02027922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
Study NCT02027922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluor Protector S
Description: Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)